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Objectives: Health disparities between individuals of African and European ancestry 
are well documented. The disparities in bipolar disorder may be driven by racial bias 
superimposed on established factors contributing to misdiagnosis, including: evolv-
ing empirically based diagnostic criteria (International Classification of Diseases 
[ICD], Research Diagnostic Criteria [RDC] and Diagnostic and Statistical Manual 
[DSM]), multiple symptom domains (i.e. mania, depression and psychosis), and multi-
modal medical and additional psychiatric comorbidity.
Methods: For this paper, we reviewed the phenomenological differences between 
bipolar individuals of African and European ancestry in the context of diagnostic cri-
teria and clinical factors that may contribute to a potential racial bias.
Results: Published data show that bipolar persons of African ancestry, compared 
with bipolar persons of non- African ancestry, are more often misdiagnosed with a 
disease other than bipolar disorder (i.e. schizophrenia). Additionally, studies show 
that there are disparities in recruiting patients of African ancestry to participate in 
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1  | INTRODUC TION
Bipolar disorder is the sixth leading cause of disability worldwide, 
and its early onset and chronic nature underscore its cumulative ill-
ness burden and the importance of early intervention and optimal 
disease management strategies.1,2 However, lack of access to and 
minimal utilization of healthcare coupled with low socioeconomic 
status continue to drive disease- related disability worldwide, in-
cluding in the USA. In comparison to the general US population, 
Americans with mental illness have decreased life expectancy; for 
people with severe mental disorders (i.e. schizophrenia, depression, 
and bipolar disorder), this life expectancy reduction ranges from 10 
to 20 years.3,4
There is a general recognition that the increased morbidity and 
mortality of people with serious mental illness may be magnified by 
racial disparities in access to, or provision of healthcare. African- 
American individuals with bipolar disorder, in comparison to white 
individuals with bipolar disorder, have been reported to have signifi-
cantly higher rates of receiving an initial clinical diagnosis other than 
bipolar disorder; this misdiagnosis may impede treatment strategies 
that can directly address illness morbidity.5-7
The patient advocacy group Depression Bipolar Support Alliance 
(formerly known as the National Depressive & Manic Depressive 
Association) conducted membership surveys, both in 1994 and 
nearly 10 years later, that continue to suggest lengthy delays 
(10+ years) in receiving an accurate diagnosis.8,9 Misdiagnosis has 
significant implications. A misdiagnosis of bipolar depression as un-
ipolar major depressive disorder with subsequent antidepressant 
treatment increases the likelihood of treatment non- response and/
or antidepressant- induced mania/mood destabilization, while a mis-
diagnosis of schizophrenia limits the opportunity for treatment with 
lithium and/or mood- stabilizing anticonvulsants, as well as access to 
bipolar evidence- based psychotherapies. With these considerations 
in mind, we reviewed psychiatry disparity literature to gain a better 
understanding of racial diagnostic differences and explore methods 
for addressing this disparity, with a focus on biological and genetic 
studies inclusive of individuals of African ancestry.
To accomplish this goal, we reviewed literature pertaining to di-
agnosis and treatment of bipolar disorder (either type I or type II) 
in people of African ancestry compared with people of non- African 
ancestry. Barriers to research inclusion and participation are also 
discussed, especially in the context of genetic research, underscor-
ing the need to address potential racial biases during diagnosis and 
treatment, and the potential hazards of not doing so. We first pres-
ent the literature chronologically to evaluate how recognition of this 
problem has evolved over the last 50 years. We then explore the 
potential effects of misdiagnosis on outcome and prognosis, and 
posit genomic studies of bipolar disorder as a possible method of 
addressing this disparity.
2  | METHODS
Literature for this descriptive review was selected using key search 
terms to target studies describing diagnostic, treatment, and out-
come differences between individuals of European and African an-
cestry, and research participation in biological research, specifically 
genetic studies, among people of African and European ancestry. 
The cited literature came from PubMed and Google Scholar searches 
with the following key terms: bipolar disorder African Americans, bi-
polar disorder African Americans treatment, bipolar disorder African 
ancestry, bipolar disorder African Americans lithium, and bipolar 
disorder blacks. To identify genetic studies, these keywords were 
searched for: bipolar disorder African ancestry genetics. A total of 
28 publications were excluded from the initial search, and 20 more 
were excluded based on pertinent content, the details of which are 
shown in Figure 1.
We retained the language used in the original publications to 
describe various racial and ethnic identifications; for example, if 
a publication described patients of African ancestry as ‘African 
American’, the term ‘African American’ was used when discussing 
the publication. In addition, race and ethnicity are terms often used 
interchangeably. The Oxford Dictionary defines ethnicity as ‘the 
fact or state of belonging to a social group that has a common na-
tional or cultural tradition’, while defining race as ‘each of the major 
divisions of humankind, having distinct physical characteristics… a 
group of people sharing the same culture, history, language, etc.; an 
ethnic group.’10 These definitions are very similar to each other and 
important genomic studies. This gap in biological research in this underrepresented 
minority may represent a missed opportunity to address potential racial differences 
in the risk and course of bipolar illness.
Conclusion: A concerted effort by the research community to increase inclusion of 
diverse persons in studies of bipolar disorder through community engagement may 
facilitate fully addressing these diagnostic and treatment disparities in bipolar indi-
viduals of African ancestry.
K E Y W O R D S
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we therefore use the terms interchangeably and retain the language 
used (either race or ethnicity) in the cited studies.
3  | E VOLUTION OF DIAGNOSTIC 
CRITERIA AND HISTORIC AL STUDIES OF 
POTENTIAL R ACIAL BIA S
Psychiatric diagnostic classification has been achieved glob-
ally through the World Health Organization (WHO) International 
Classification of Diseases (ICD), starting with the ICD6 in 1948, and 
the Diagnostic and Statistical Manual (DSM), published in the USA 
by the American Psychiatric Association (APA).11 Primarily based 
on dynamic formulation, manic- depressive ‘reaction’ and ‘illness’ 
were first classified in DSM I (1952) and DSM II (1968), respectively. 
Informed by earlier work used to develop the Research Diagnostic 
Criteria (RDC) and DSM III (1980), empirically based, contemporary 
diagnostic categorization based on specific, descriptive, and reliable 
inclusion/exclusion criteria with inter- observer reliability and stabil-
ity was introduced in DSM IIIR (1987). DSM IIIR marked a funda-
mental shift away from a predominantly psychodynamic theoretical 
influence toward a biomedical model.12
A second diagnostic debate, during this time of ICD and DSM 
classification revision, was whether psychosis in affective disor-
der represented a separate disease process from schizophrenia.13 
Internationally, more so than nationally in the USA, there was a 
movement to adapt a broader concept or spectrum of affective 
psychosis. For example, a UK vs USA comparative study by Cooper 
et al. in 1972 found that, despite similar clinical presentations, there 
was a significant difference in the diagnostic rates of schizophre-
nia (New York, 62%; London, 34%), psychotic depression (five times 
higher in London), and mania (12 times higher in London).14 The late 
entrance of lithium carbonate into the US pharmacopoeia in 1970 
(the USA was the 50th country to admit lithium to the world mar-
ketplace) as well as further refinement of diagnostic criteria (DSM 
III, RDC and DSM IIIR) began to slowly shift the US diagnostic 
practice and started to address the misdiagnosis of bipolar disor-
der.15 However, the misdiagnosis remains prevalent, especially in 
African- American and African- Caribbean individuals.5,16 The evolu-
tion of biomedical diagnostic criteria, increasing recognition of an 
affective spectrum concept including psychosis, and the first Food 
and Drug Administration (FDA)- approved medication for bipolar dis-
order introduced in the USA more than 15 years after FDA approval 
of antipsychotic chlorpromazine (1954) and nearly 10 years after 
FDA approval of antidepressant amitriptyline (1961) are relevant 
historical events to better understand the African- American bipolar 
patient experience. Additional clinical factors that may be associ-
ated with the misdiagnosis of bipolar disorder have included: stage 
of mania when seeking treatment, hospital setting where diagnosis is 
made, symptom presentation, and clinical interpretation of symptom 
presentation.
A case series of three African- American people with psychotic bi-
polar disorder (two male and one female) diagnosed as schizophrenic 
at a university hospital in New Jersey suggested that misdiagnosis 
was, in part, related to delays in seeking care. The investigators ob-
served that hypomanic or manic behavior ‘may be more easily tol-
erated than it would be in a higher socioeconomic area’ (vs the low 
socioeconomic area reported  in the study).17 Classic Kraepelinian 
observations have suggested that, as an episode of mania progresses, 
euphoria decreases and risk of psychosis increases.18 Therefore, in-
dividuals with bipolar disorder who delay seeking treatment may be 
more likely to display psychotic symptoms once they present to a 
medical center for a cross- sectional, non- longitudinal assessment. 
Of note, there have been no systematic studies of the contribution 
of treatment- seeking delay to misdiagnosis in bipolar individuals.
A 1983 medical record review compared rates of misdiag-
nosis among 76 bipolar individuals (Hispanic, 18 [23.4%]; black, 
21 [27.3%]; white, 37 [48.1%]) treated in an outpatient depart-
ment of an inner- city New York hospital. A greater proportion 
of black and Hispanic individuals with bipolar disorder were 
previously misdiagnosed with schizophrenia compared to white 
individuals (schizophrenia: 85.7% and 83.3% vs 51.4%; paranoid 
F IGURE  1 Flow diagram for literature 
selection and inclusion
Manuscripts excluded: No full 
text, poster presentation, or did 
not meet criteria of clinical 
research (based on content 
relating to bipolar disorder 
diagnosis and treatment and 
research participation in different 
races/ethnicities, as well as 
genomic research in bipolar 
disorder)
Abstracts reviewed after non-eligible 
articles removed 
(N = 66) 
Main Search Criteria: 
‘African-American bipolar disorder’ 
Databases: 
PubMed and Google Scholar 
(N = 93) 
Literature included in systematic
review (final decisions made by 
author #s 1, 2, 3, 6, 12 and 13)
(N = 46) 
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schizophrenia: 66.7% and 33.3% vs 18.9% for black, Hispanic and 
white individuals, respectively; P < .0005 and P < .005, respec-
tively). As none of the individuals had a history of clinical diag-
noses of a non- affective psychosis, ethnicity was concluded to 
be a significant factor in their misdiagnosis.6 A larger 2004 study 
explored the relationship between ethnicity, symptom presenta-
tion, and diagnosis. African- Americans were four times as likely to 
have a schizophrenia diagnosis when compared to otherwise sim-
ilar white Americans (odds ratio [OR] = 4.05, 95% confidence in-
terval [CI]: 3.91- 4.19)7 in analyses of the Veteran’s Administration 
Medical Center National Psychosis Registry (n = 134 523; 48 443 
[36.9%] bipolar, 14 717 [10.9%] schizoaffective) that adjusted 
for potential demographic confounds. Furthermore, the lack of 
significant ethnic differences in positive and negative moderate 
symptom severity also suggests equivalent symptom burden but 
different clinical interpretation of diagnostic information. While 
these historical studies identify racial/ethnic bias as a contribu-
tor to misdiagnosis, more contemporary research (with enhanced 
study methodology) may suggest strategies to correct for these 
differences.
The Epidemiologic Catchment Area Study (ECA) was a landmark 
study that examined the utilization of a structured diagnostic inter-
view suitable for administration by lay interviewers in a community- 
based setting. The diagnostic interview was administered to five sites 
of different sizes and resident characteristics (n = 20 000; New Haven, 
CT, Baltimore, MD, St. Louis, MO, Durham, NC, and Los Angeles, CA). 
While the percentage of black respondents at each site ranged from 4% 
to 34%, there was no significant difference in rates of bipolar disorder 
by race, suggesting the value of a highly structured research diagnostic 
interview as a data source to reduce clinical interpretative differences 
among persons of different races and ethnicities.19
Critical investigations from the University of Cincinnati First- 
Episode Psychosis and Mania Projects not only used structured 
diagnostic interviews, as done in the ECA study, but also used a 
multi- racial expert- consensus diagnostic panel of psychiatrists 
blind to ethnicity to reveal possible limitations, or biases, when 
clinical diagnoses are the sole source of patient data.5,20 The first 
project enrolled 100 people (46% African- American and 54% 
Caucasian) from inpatient psychiatry services. The investigators 
evaluated the differences in clinical diagnoses made at the initial 
point of care (the Psychiatric Emergency Service) vs diagnoses 
made once patients were admitted to the inpatient unit where 
they underwent a research Structural Clinical Interview for DSM- 
III- R. African- American bipolar individuals, in comparison to 
Caucasian bipolar individuals, were more likely to be diagnosed in 
the Emergency Department with non- affective psychosis in gen-
eral (i.e. schizophrenia + psychosis not otherwise specified [NOS]; 
33% vs 13%, respectively; P = .03) and, in particular, with schizo-
phrenia (20% in African- Americans vs 7% in white individuals; 
P = .07).5 In the second project, 195 African- American and white 
individuals with at least one psychotic symptom were recruited 
between 1998 and 2001. Of these, 79 (39 African- Americans and 
40 white individuals) received a bipolar disorder diagnosis by an 
expert consensus blind to ethnicity. After controlling for demo-
graphic variables and comorbid drug use, African- American men 
with bipolar disorder had significantly higher rates of clinical 
schizophrenia diagnoses (25% vs 7%, respectively; P = .02) and 
higher rates of schizophrenia diagnosis by structured interview 
(29% vs 15%; P < .03) when compared to the other patient groups. 
Rates of first- rank psychotic symptoms did not differ by ethnic 
group, suggesting that the patient’s race and sex were primary fac-
tors for schizophrenia diagnosis.20 The use of an expert panel re-
viewing diagnostic criteria, in comparison to both clinical diagnosis 
and structured interview, appeared to yield less misdiagnosis.
The evolution of bipolar disorder diagnostic criteria coincides with 
these inaugural efforts to understand differences in diagnosis between 
bipolar individuals of European and African ancestry. Reports suggest 
that these differences are mainly attributable to racial/ethnic bias and/
or misattribution of psychotic symptoms. These historical and distinc-
tive studies are key to understanding the development of this disparity 
and its impact on subsequent treatment (Figure 2).
4  | TRE ATMENT, RESPONSE ,  AND 
PROGNOSIS
A 2002 prospective longitudinal study reported that 24 African- 
Americans with bipolar I disorder received antipsychotics at a 
F IGURE  2 Timeline of historical 
clinical and diagnostic studies addressing 
racial differences and potential bias. AA, 
African- American; CA, Caucasian; Hosp, 
hospital; NY, New York
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greater percentage of follow- up visits (44%/70 visits) than 34 white 
individuals (40%/34 visits; P < .007). The prescription of typical 
antipsychotics in African- American vs white bipolar individuals 
was significantly higher (38% vs 15%, respectively; P < .05).21 A 
larger 2003 cross- sectional study of 535 hospitalized individuals 
with bipolar disorder confirmed this earlier observation as African- 
Americans, in comparison to white patients, were prescribed antip-
sychotic medications at a higher rate (92% vs 62%, respectively); 
there was no difference, however, in the use of atypical vs typical 
antipsychotics.22 While first- generation or typical antipsychotics 
are well known to be very effective in treating acute mania, they 
have a higher incidence (in comparison to FDA second- generation 
or atypical antipsychotics) of mood destabilization (i.e. post manic 
depression) and extrapyramidal side effects including tardive dys-
kinesia.23 Adverse effects such as these warrant strong efforts to-
ward understanding the root cause of misdiagnosis and inevitable 
suboptimal treatment.
A study that examined 34 bipolar persons taking lithium car-
bonate demonstrated that African- Americans had a mean lithium 
red blood cell (RBC)/plasma ratio (39.70 ± 17.8; n = 12) that was sig-
nificantly higher than that of white individuals (26.12 ± 10.9; n = 22; 
P < .05). The side effect burden was similarly higher in African- 
Americans vs white patients even though the two groups did not 
significantly differ in mean daily dose (1131 mg/day vs 1159 mg/day, 
respectively) and average plasma level (0.58 ± 0.27 vs 0.57 ± 0.17, 
respectively). The RBC measurement has been proposed to be a bet-
ter measure of brain lithium level than conventional plasma levels, 
and earlier research has suggested that African- Americans, in com-
parison to Caucasians, have reduced efficiency in the RBC lithium 
sodium counter transport pathway.24-26 Lower dose lithium proved 
to have positive results in a more recent study from 2015 that exam-
ined 283 bipolar patients who participated in a 6- month, random-
ized, double- blind, placebo- controlled trial of adjunctive low- dose 
lithium (600 mg) with optimized treatment (LiTMUS). Compared to 
white participants, African- Americans had a greater reduction of de-
pression symptoms (P = .04) and improved quality of life (P = .03). 
Although the study showed promising support for low- dose lithium 
in African- Americans, larger sample sizes in future studies are nec-
essary to confirm these significant findings.27 Underutilization of 
mood stabilizers or suboptimal dosing of mood stabilizers may nega-
tively affect disease progression.
Gonzalez et al. compared 1- year treatment outcomes from the 
US Systematic Treatment Enhancement Program for Bipolar Disorder 
(STEP- BD) among African- American, Hispanic, and white individuals. 
African- Americans (n = 155) with psychotic symptoms at baseline, 
in comparison to non- Hispanic white individuals (n = 729) with psy-
chotic symptoms at baseline, had a significantly lower response rate 
(50% reduction in Montogomery- Asberg Depression Rating Scale 
[MADRS]) and recovery rate defined as remission of symptoms over 
the 1- year period (38% vs 53%, respectively; P < .07). The investiga-
tors did note that symptom reports, during the clinical assessment, 
from some African- Americans may have been misattributed to psy-
chopathology instead of sociocultural background. For example, the 
authors proposed that a persecutory delusion classified as a psy-
chotic symptom may have been more accurate to view as an anxiety 
symptom when sociocultural context was considered.28 This mis-
attribution could fuel unsuitable treatment recommendations (i.e. 
using antipsychotic vs anti- anxiety treatment). This study suggests 
that culturally competent treatment regimens in populations with 
different sociocultural background may help address racial bias and 
aid in yielding more appropriate treatment recommendations.
Consideration of sociocultural background may also be crucial 
regarding continuity of outpatient care. A 2005 Veterans Affairs 
(VA) National Patient Care Database study of veterans with bi-
polar disorder (n = 2316; African- Americans = 303) revealed that 
African- Americans were significantly less likely to have an outpatient 
follow- up visit within 90 days of their diagnosis compared to white in-
dividuals (13% African- Americans vs 87% white individuals; P = .009). 
The investigators suggested that the reduced likelihood of African- 
Americans receiving adequate outpatient care compared to white 
individuals may be due to lack of culturally competent providers, par-
ticularly in urban facilities.29 A study from 2014 using the National 
Comorbidity Survey Replication (NSC- R; a US study of mental health) 
further examined the difference in treatment of bipolar disorder be-
tween black (n = 30) and white (n = 137) Americans. No black patients 
received minimally adequate treatment (defined as use of a mood 
stabilizer alone or in combination with an antipsychotic) in the previ-
ous year, compared to 17% of white patients who did (P < .05). Their 
findings suggest that, in general, people with bipolar disorder receive 
inadequate treatment that is then further confounded by race.30
Disparities in treatment regimens and subsequent lower qual-
ity outcomes warrant targeted treatment models aimed at improv-
ing outcomes and reducing health disparities. Specialized Care for 
Bipolar Disorder (SCBD) and Enhanced Clinical Intervention (ECI) 
are examples of such treatment regimens. The study that devel-
oped these treatment models sought to reduce health disparities 
in three groups often underrepresented in clinical trials: the young 
and elderly, African Americans, and rural residents with bipo-
lar disorder. The ECI component was intensive case management 
adapted to the specific needs of each subpopulation focused on 
education about the mood disorder itself and treatment strategies. 
A total of 463 bipolar individuals (68 African- American and 385 
Caucasian) were randomly assigned to SCBD alone or SCBD + ECI 
for up to 3 years. While the study results showed that improve-
ment in quality of life was greater in the SCBD + ECI group, there 
were no significant differences by race, suggesting the benefit of 
culturally competent case management and standardized treat-
ment protocols.31 If personalized treatment protocols are to be 
developed, understanding the patient’s sociocultural background 
is just as important as the diagnostic criteria of bipolar disorder in 
African- Americans (Table 1). Biologically based definitions of bipo-
lar disorder and psychotic symptoms are also valuable, but early 
in validation and development. Further advancement of clinically 
relevant biomarkers (through biological and/or genetic studies of 
the neurobiology of the disease) is an important step to addressing 
these disparities.32
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5  | GENOMIC STUDIES OF BIPOL AR 
DISORDER: UNDERREPRESENTATION OF 
POPUL ATIONS OF AFRIC AN ANCESTRY
Understanding the genetic basis of bipolar disorder could greatly ad-
vance knowledge of its neurobiology and etiology. Bipolar disorder is 
a complex genetic disorder, with heritability estimated to be between 
60% and 85%, indicating that a large proportion of disease risk is po-
tentially attributed to inter- individual genetic variation.33 Numerous 
studies have attempted to identify genetic factors contributing to the 
risk of bipolar disorder to uncover the underlying pathophysiology 
and pathogenesis of the disease. While genomic research could aid 
in resolving health disparities, others have argued that knowledge of 
genetic factors that contribute to illness or treatment outcomes will 
not itself reduce health disparities. Kashyap and colleagues note that, 
although the role of genomics in health disparities is quite complex, it 
is critical to understand how genetic variation influences the health 
and well- being of at- risk communities to eliminate health disparities in 
the USA.34 On the other hand, West et al.35 argue that clarification of 
genetic contributors to disease etiology will not help to provide ways 
to address disparities, as they are rooted in social, material, and envi-
ronmental conditions. Nevertheless, there is recognition that genetic 
studies should include diverse populations to enable identification of 
a wide range of genetic variation contributing to health outcomes and 
ensure that knowledge gained from these studies is applicable to all 
populations.
Numerous studies have been conducted to investigate the genet-
ics of bipolar disorder, including many candidate gene studies, a grow-
ing number of genome- wide association studies (GWASs), and recently 
introduced whole exome and whole genome sequencing studies. 
These genetic association studies and the efforts of large international 
consortia, particularly the Psychiatric Genomics Consortium (PGC), 
have led to the discovery of several bipolar disorder risk variants with 
genome- wide significant evidence of association.36 While these dis-
coveries constitute important progress toward a better understanding 
of the neurobiology of the disease, the studies that produced these 
results were performed almost exclusively in populations of European 
ancestry. Very few studies of the genetics of bipolar disorder, and 
only one published GWAS, have included samples of African ancestry. 
That GWAS included only 345 African- American cases, a small num-
ber compared with the 1001 European- American cases in the same 
study, providing inadequate power to detect genetic associations in 
the African- American subset.37 The small sample size of the published 
African- American GWAS of bipolar disorder is in stark contrast to the 
TABLE  1 Studies addressing treatment and drug response in bipolar patients of African ancestry
Study Sample size (N or % total) Major conclusions
Szarek et al.22 Total = 535 hospitalized inpatients Both AA and HIS were more likely to have antipsychotics prescribed 
(92% and 85%, respectively) compared with CA (62.2%)
Fleck et al.21 Total = 58 outpatients 
AA = 24 (41.3%) 
CA = 34 (58.6%)
AA received antipsychotics during a greater percentage of follow- up 
treatments compared with CA (mean = 70 [44%] vs mean = 34 
[40%]; P < .007)
Fagiolini et al.31 Total N = 463 
AA = 68 (14.7%) 
CA = 385 (83.2%)
There was no significant difference found between participants of 
different race. However, adding ECI to SCBD showed benefits of 
greater QOL
Gonzalez et al.28 Total = 1858 
AA = 155 (8.3%) 
CA = 1551 (83.5%)
For depression response (measured by the MADRS), AA with 
psychotic symptoms at baseline had poorer outcomes compared 
with non- HIS CA with psychotic symptoms at baseline (total 
recovered/responded: AA = 38 vs CA = 241; P = .339) (recovered/
responded = 50% improvement over baseline)
Kilbourne et al.29 Total BD I = 2316 
AA = 303 (13.1%)
AA patients were less likely to receive suitable outpatient care 
within 90 days of the index bipolar diagnosis compared with CA 
patients (202 vs 1351; P = .009)
Johnson et al.30 Total = 167 
AA = 30 (18%) 
CA = 137 (82%)
Minimally adequate treatment (defined as use of a mood stabilizer 
alone or in combination with an antipsychotic) was significantly 
different in AA vs CA (0% vs 17%; P < .05)
Strickland et al.24 Total = 34 
AA = 12 
CA = 22
There were higher lithium red blood cell/plasma ratios and side 
effects in AA vs CA (39.70 ± 17.84 vs 26.12 ± 10.95; P < .05)
Gonzalez Arnold et al.27 Total = 283 
AA = 47 (19.7%) 
CA = 175 (61.8%) 
HIS = 39 (13.8%) 
(cohort included those with self- identified 
race)
AA on low- dose lithium (600 mg average dosage), compared with 
CA, had greater improvement on depression symptoms (P = .04) 
and improved QOL scores (P = .03)
AA, African- American; CA, Caucasian; ECI, enhanced clinical intervention; HIS, Hispanic; MADRS; the Montgomery- Åsberg Depression Rating Scale; 
QOL, quality of life; SCBD, specialized care for bipolar disorder.
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large number of European ancestry cases that the PGC has accumu-
lated (n = 9784, to date), leading to the discovery of more than a dozen 
genetic variants contributing to bipolar disorder risk in European pop-
ulations38 (Figure 3). Similarly, in reviewing GWASs of psychiatric 
pharmacogenomics, Murphy and McMahon noted that ‘non- European 
groups were underrepresented in these studies’.39
The underrepresentation of individuals of African ancestry in ge-
netic studies is a two- fold issue stemming from both the small numbers 
of African- ancestry participants and the frequent exclusion of partici-
pating minorities from analyses to promote sample homogeneity and 
prevent confounding by population stratification. The low participation 
rate of African- Americans in bipolar disorder genetic research speaks 
to the need to increase engagement of these populations in research; 
however, recruitment of African- Americans for genetic research (and 
bipolar disorder studies more specifically) is challenging40 (Table 2). 
For example, the Mayo Clinic Bipolar Biobank has about 2148 indi-
viduals enrolled, but only 3.7% are of African ancestry.41 Even with 
policy initiatives from the National Institute of Mental Health (NIMH) 
aimed at increasing minority participation, results have been mixed. 
Nwulia et al.42 assessed participants in the US Bipolar Genome Study 
to identify concerns that influence individual participation in psychi-
atric genetic studies, and found that there is an increased perception 
of harmful consequences among black individuals, when compared 
to white individuals. The authors also reported that another main 
concern among black individuals when compared to white individuals 
was racial discrimination (34% of African- Americans were ‘very con-
cerned’ compared to 13% of white individuals; P < .0001), and noted 
that there may be additional factors contributing to the decision to 
participate in research. To better understand what factors influence 
patient participation, Hartz et al.40 used a large, population- based 
sample from a genetic study of nicotine dependence (Collaborative 
Study on the Genetics of Nicotine Independence) to investigate 
differences between European- American (n = 705) and African- 
American (n = 352) participation. They examined three critical steps 
of study recruitment: establishment of initial contact, participation in 
screening, and recruitment into the genetic study (with blood draw). 
Surprisingly, the participation rate was lower in European- Americans 
than in African- Americans (57% vs 71%, respectively; P < .0001). This 
difference was because willingness to participate was not seen as a 
major barrier; once reached, minorities were more likely to participate. 
Locating minority participants and establishing contact were the key 
barriers, suggesting that recruitment efforts should focus on areas 
with a high frequency of individuals of African ancestry.
Another recent study43 assessed willingness to participate in 
a biobank, hypothesizing that willingness would be higher under 
more restrictive scenarios. Participants (n = 13 000; African- 
Americans = 1483; white individuals = 6521) were randomized to 
receive a survey in one of three hypothetical biobank scenarios; all 
scenarios were the same except for consent type and data sharing 
approach. In this study, African- American participants expressed 
lower levels of willingness to participate compared to white partici-
pants (56% vs 70%, respectively). However, few studies have aimed 
to understand how to overcome barriers to study participation and 
inclusion. The STEP- BD created the Community Partner Program 
(CPP) to address the issue of underrepresented minorities in mental 
health research studies. Community sites enrolled higher percentages 
of minority participants when compared to collaborating academic 
sites (45.2% vs 15.3%, respectively; P < .001). The inception of such 
programs is essential and demonstrates that including community 
partners greatly enhances minority involvement in research studies. 
Moreover, community- engaged participatory- based research remains 
crucial to motivating individuals to consistently participate in research 
activities.44 These research activities are key to conducting impactful 
studies that will enhance understanding of the biological and genetic 
basis of bipolar disorder, which can possibly address previously ob-
served symptomatic differences that lead to misdiagnosis of bipolar 
African- Americans.
6  | CONCLUSION AND FUTURE 
DIREC TIONS
This paper has reviewed the racial disparities in bipolar disorder di-
agnosis, treatment, and research participation, emphasizing the need 
for increased efforts by the scientific community to address these dis-
parities. The reviewed literature suggests that people of African an-
cestry with bipolar disorder (either type I or II) have higher rates of 
F IGURE  3 Sample sizes of the largest African- American and 
European-American bipolar disorder genome- wide association 
study published to date; Based on reference numbers 36 and 37 
[Colour figure can be viewed at wileyonlinelibrary.com]
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misdiagnosis in comparison to people of non- African ancestry with bi-
polar disorder. These disparities have developed and persisted despite 
revision of diagnostic criteria from a psychodynamic formulation to a 
biomedical model, increasing recognition of an affective spectrum, and 
a bipolar pharmacopoeia, at least in the USA, developed 10- 15 years 
later than treatments for schizophrenia and major depression.
This descriptive review has a number of limitations. While focused 
on biological research as a means to address health disparities, there 
needs to be recognition that many additional factors may contribute to 
a bipolar misdiagnosis and these factors may not be unique to patients 
of African ancestry. There are socioeconomic, cultural, and health-
care administrative aspects of access to and benefit from a bipolar 
diagnosis and treatment program that go beyond race and ethnicity. 
While this review focused on biological and genetic factors of bipo-
lar disorder, other additional non- biological and historical factors may 
contribute to this health disparity. Systematic issues such as access to 
the healthcare system and historical mistrust may also play a role. The 
mechanisms and processes contributing to this important issue likely 
involve slavery, institutional racism, discrimination, poverty, and seg-
regation. The focus on genomic and community- based participatory 
research is meant to be an alternative approach to address these dis-
parities and not reduce the importance of other contributing factors.
We proposed a plan of action to address these disparities that 
involves understanding the evolution of the problem, and identify-
ing the contribution of associated clinical and biological risk factors 
of bipolar disorder, particularly through genomic studies. Targeted, 
biologically based research focused on these differences has the po-
tential to clarify the issues and effect change in the psychiatric care 
of minority populations.44 However, low rates of research participa-
tion among minority populations compound the problem because 
low numbers preclude comprehensive evaluation of potential bio-
logic and cultural factors that may contribute to possible differences 
in clinical presentation and disease progression. Low research par-
ticipation is best addressed through increased understanding of the 
barriers to engagement with minority communities as well as strong 
efforts from the scientific community to include minority persons 
in studies of bipolar disorder, especially genetic and other etiologic 
studies.45 Examples of active engagement efforts include, but are not 
limited to: community- based participatory research (CBPR) focused 
on patient and family education, working with faith- based organi-
zations to disseminate impactful and educational research findings, 
focused efforts to train more psychiatrists in cultural competency, 
and overall training of more psychiatrists of African ancestry.46
The complexities of the factors that contribute to misdiagnosis of 
bipolar disorder in individuals of African ancestry and minimal partic-
ipation from minority samples are critical disparities that warrant at-
tention and action from the scientific community and facilitators.
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